Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

Shire’s Vpriv recommended for European approval

June 28, 2010 Sales and Marketing Brinavess, Gaucher, Rapiscan, Ruconest, Shire, Sycrest

Shire has won backing from a key European regulatory committee for its new Gaucher disease orphan drug. Vpriv was one …
News
Claudio_Albrecht_CEO

Actavis appoints Dr Claudio Albrecht

June 28, 2010 Sales and Marketing Actavis, appointment, sales and marketing

Icelandic generics company Actavis has appointed Dr Claudio Albrecht as its new chief executive. He formerly led Ratiopharm and has …
Appointment

New anti-clotting drugs: stopping the silent killers

June 28, 2010 Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis

Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …
Feature
Langland

Langland and Dr Foster share top honours at Best of Health

June 25, 2010 Medical Communications, Sales and Marketing Best of Health, IPA, awards

Dr Foster Intelligence and Langland were awarded the most prestigious ‘Best of Show’ awards at the 2010 IPA Best of …
News

Sanofi licences novel oral anti-diabetic treatment

June 25, 2010 Research and Development, Sales and Marketing Metabolex, Sanofi-Aventis, diabetes

Sanofi-Aventis has signed an exclusive worldwide licensing agreement with US-based diabetes specialist Metabolex for a novel oral anti-diabetic treatment. MBX-2982 …
News

NICE re-thinks arthritis guidance

June 25, 2010 Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis

NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …
News
Pfizer iPad app

Digital Pharma: First pharma iPad apps

June 25, 2010 Medical Communications, Sales and Marketing Apple, Pfizer, Sanofi, app, ipad, iphone

The first big pharma apps specially designed for Apple’s iPad have started to emerge, with Pfizer and Sanofi leading the …
News

NICE rejects Glivec as adjuvant therapy

June 24, 2010 Sales and Marketing Glivec, NICE, Novartis

NICE has rejected the use of Novartis’ Glivec as an adjuvant treatment for people who have had a gastrointestinal stromal …
News
George Osborne

Mixed reaction for Osborne’s first Budget

June 23, 2010 Research and Development, Sales and Marketing biotech, pharma, tax, tax relief

George Osborne’s first Budget as chancellor has had a mixed reception from the pharma and biotech sectors. The BioIndustry Association …
News

Pfizer withdraws blood cancer drug in US

June 22, 2010 Sales and Marketing AML, Mylotarg, Pfizer, blood cancer

The US regulatory body has withdrawn Pfizer’s leukaemia drug Mylotarg after it was linked to a number of deaths, and …
News
NDA_Panos

NDA appoints Dr Panos Tsintis

June 22, 2010 Sales and Marketing NDA, appointment, sales and marketing

European regulatory affairs consulting group NDA has appointed Dr Panos Tsintis medical advisor to NDA Regulatory Science in a move …
Appointment
Andrew Witty

Let’s avoid further stand-offs, says Witty

June 22, 2010 Research and Development, Sales and Marketing EFPIA, Greece, industry, pricing

Pharma will need to find new ways of working with European governments in order to avoid further crises as witnessed …
News
GW laboratory

Bayer launches world’s first cannabis-derived prescription drug

June 21, 2010 Sales and Marketing Bayer, GW Pharmaceuticals, Sativex

Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK. Sativex treats the spasticity symptoms of multiple …
News

GSK tops access to medicines ranking

June 21, 2010 Sales and Marketing GlaxoSmithKline, developing world, medicines access

GlaxoSmithKline does the most of any pharma manufacturer to improve access to medicines needed in the developing world, according to …
News

Tasigna more effective than Glivec, says Novartis

June 21, 2010 Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia

Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …
News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026